Effects of native human leukocyte interferon-α and recombinant human interferon-α on P3-X63-Ag8.653 mouse myeloma cell growth

Journal of International Medical Research

Volumn 37, Issue 5, 2009, Pages 1570-1576

  Plesničar, Andrej ^a   Vidmar, G ^b   Stabuc B ^a   Plesničar, B Kores ^c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY REHABILITATION INSTITUTE   (Slovenia)

^c UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

Cytokines; In vitro cell growth; Multiple myeloma; Native human leukocyte interferon (nhIFN ); P3 X63 Ag8.653 mouse myeloma cell line; Recombinant human interferon 2a (rhIFN 2a); Recombinant human interferon 2b (rhIFN 2b)

Indexed keywords

ALPHA INTERFERON; NATIVE HUMAN INTERFERON ALPHA; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH CURVE; IN VITRO STUDY; MOUSE; MYELOMA CELL; NONHUMAN;

EID: 70449686477     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700535     Document Type: Article

References (28)

1. Barlogie B, Shaughnessy J, Epstein J, et al: Plasma cell myeloma. In: Williams Hematology, 7th edn (Lichtman MA, Beutler E, Kipps TJ, et al, eds). New York: McGraw-Hill Professional Publishing, 2005; pp 1501 - 1533.
2. Munshi NC, Longo DL, Anderson KC: Plasma cell disorders. In: Harrison's Principles of Internal Medicine, 17th edn (Fauci AS, Braunwald E, Kasper DL, et al, eds). New York: McGraw-Hill Medical Publishing, 2008; pp 700 - 707.
3. Joshua DE: Multiple myeloma. In: Cancer Facts. A Concise Oncology Text, 1st edn (Bishop JF, ed). Amsterdam: Harwood Academic Publishers, 1999; pp 301 - 305.
4. Raman D, Baugher PJ, Thu YM, et al: Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137-165.
5. Fritz E, Ludwig H: Interferon-α treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11: 1427-1436.
6. Bladé J, Esteve J: Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients. Med Oncol 2000; 17: 77-84. (Pubitemid 30367835)
7. The Myeloma Trialists' Collaborative Group: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034.
8. Dürk HA: Maintenance therapy for multiple myeloma with particular emphasis on thalidomide. Onkologie 2006; 29: 582-590. (Pubitemid 46005783)
9. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936. (Pubitemid 46638847)
10. Bladé J, Lopez-Guillermo A, Tassies D, et al: Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991; 79: 523-525.
11. Sawamura M, Murayama K, Ui G, et al: Plasma cell leukaemia with alpha-interferon therapy in myeloma. Br J Haematol 1992; 82: 631.
12. Jelinek D, Arora T: Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness. Curr Top Microbiol Immunol 1997; 224: 261-268. (Pubitemid 27368563)
13. Puthier D, Thabard W, Rapp MJ, et al: Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br J Haematol 2001; 112: 358-363. (Pubitemid 32183477)
14. Mellstedt H, Åhre A, Björkholm M, et al: Interferon therapy in myelomatosis. Lancet 1979; i: 245-247.
15. Osterborg A, Björkholm M, Björeman M, et al: Natural interferon-α in combination with melphalan/prednisone versus melphalan/ prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428-1434. (Pubitemid 23083819)
16. Zidovec S, Mažuran R: Sendai virus induces various cytokines in human peripheral blood leukocytes: different susceptibility of cytokine molecules to low pH. Cytokine 1999; 11: 140-143. (Pubitemid 29116552)
17. Šantak G, Šantak M, Forčić D: Native human IFN-α is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-α. J Interferon Cytokine Res 2007; 27: 481-490.
18. Wilson AP: Cytotoxicity and viability assays. In: Animal Cell Culture. A Practical Approach, 2nd edn (Freshney RI, ed). Oxford: Oxford University Press, 1994; pp 263 - 303.
19. Vaiopoulos G, Viniou N, Plata E, et al: Development of plasma cell tumors during treatment of multiple myeloma. Ann Hematol 1996; 72: 317-320. (Pubitemid 26169636)
20. Egle A, Villunger A, Kos M, et al: Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 1996; 26: 3119-3126. (Pubitemid 26411522)
21. Ferlin-Bezombes M, Jourdan M, Liautard J, et al: IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998; 15: 2692-2699. (Pubitemid 28425686)
22. Cheriyath V, Glaser KB, Waring JF, et al: G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest 2007; 117: 3107-3117. (Pubitemid 47529640)
23. 2)-dependent human bone marrow-derived myeloma cell lines. J Exp Med 1989; 169: 339-344.
24. Jourdan M, Veyrune JL, De Vos J, et al: A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22: 2950-2959. (Pubitemid 36648922)
25. Desmyter J, Rawls WE, Melnick JL: A human interferon that crosses the species line. Proc Natl Acad Sci USA 1968; 59: 69-76.
26. Greenberg PL, Mosny SA: Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res 1977; 37: 1794-1799.
27. 3 and interferon-α on FO myeloma cells. Chemotherapy 2004; 50: 190-193.
28. Drexler HG, Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 2000; 24: 681-703. (Pubitemid 30495502)